Asunto(s)
Encéfalo/efectos de los fármacos , Iris/efectos de los fármacos , Inhibidores de la Monoaminooxidasa/farmacología , Tronco Encefálico/efectos de los fármacos , Tronco Encefálico/metabolismo , Núcleo Caudado/efectos de los fármacos , Núcleo Caudado/metabolismo , Clorpromazina/uso terapéutico , Depresión/tratamiento farmacológico , Depresión/metabolismo , Dopamina/metabolismo , Sinergismo Farmacológico , Humanos , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Inhibidores de la Monoaminooxidasa/uso terapéutico , Midriáticos , Norepinefrina/metabolismo , Enfermedad de Parkinson/metabolismo , Serotonina/metabolismoRESUMEN
The concentrations of 5-hydroxytryptamine (5HT), noradrenaline, and dopamine were estimated post mortem in brain stem, hypothalamus, and caudate nucleus in 33 patients who had been treated with isocarboxazid, clorgyline, or tranylcypromine and 11 controls. Similar and highly significant increases in 5HT and noradrenaline concentration occurred with all three drugs. The distribution was unimodal, but about a quarter of the patients showed only a small increase in brain amines. Tranylcypromine seemed to have a significantly greater effect on dopamine in caudate nucleus and hypothalamus compared with isocarboxazid and clorgyline. In the doses used chlorpromazine did not reduce the amine concentrations. Four patients with Parkinson's syndrome had low concentrations of dopamine in caudate nucleus in spite of monoamine oxidase inhibitor administration.